2019 AIChE Annual Meeting
(335h) A Totally Recombinant Fibrin Matrix for Mesenchymal Stem Cell Culture and Delivery
Authors
Ou Wang - Presenter, University of Nebraska-Lincoln
Ayman Ismail, University of Nebraska-Lincoln
Frank. M Fabian, University of Nebraska-Lincoln
Haishuang Lin, University of Nebraska, Lincoln
Qiang Li, University of Nebraska, Lincoln
William H. Velander, University of Nebraska-Lincoln
Srivatsan Kidambi, University of Nebraska - Lincoln
Yuguo Leo Lei, University of Nebraska - Lincoln
Mesenchymal stem cells (MSCs) have been widely studied for tissue engineering and treating diseases in laboratories, clinical trials, and clinics. Fibrin matrices are often used to culture MSCs or increase the retention of MSCs at the injection site. However, fibrins made with the human plasma derived fibrinogen have high cost and risk of human pathogen transmission. In this article, we studied if fibrin matrices made with recombinant human fibrinogen, recombinant human thrombin, and recombinant human factor XIII could be used to culture and deliver MSCs. We systematically investigated the relationships between the fibrin matrix formulation, its nanostructure, and the behaviors of the cells in the matrix including the cell morphology, viability, and growth. We found that the fibrinogen concentration significantly affected the matrix structure and cell behaviors. We then used an optimized fibrin matrix to deliver human MSCs into mice subcutaneously. We found that the matrix could significantly enhance the retention of MSCs at the injection site. To our best knowledge, this is the first study on using fibrin matrices made with entirely recombinant proteins for culturing and delivering MSCs. (Published in J Biomed Mater Res Part A: 106A: 3135â3142, 2018.)